ArticleFrontiers in cellular and infection microbiology2025
Expression of BVDV E2 protein in CHO-S cells and development of an indirect ELISA for serological detection.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recombinant LGR4 extracellular domain attenuates osteoclastogenesis and prevents bone metastasis via RANKL inhibition.Journal of bone oncology · 2026Article
- Development and Validation of a Recombinant VP2-Based Indirect ELISA for Canine Parvovirus.Microorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bovine viral diarrhea virus (BVDV) causes ongoing economic losses to the livestock industry. Monitoring antibodies via enzyme-linked immunosorbent assay (ELISA) is a key tool for ensuring the eradication of BVDV from cattle herds. We developed an indirect ELISA (rE2-iELISA) using CHO-S-expressed recombinant E2 protein, the major immunogenic glycoprotein mediating viral attachment and immune evasion. Optimized assay conditions included: 0.4 μg/well antigen coating, 5% BSA blocking, 1:100 serum dilution, and 1:5000 secondary antibody dilution. The assay demonstrated exclusive specificity for BVDV-1 and BVDV-2 with detection sensitivity to 1:1,500 serum dilution. Validation revealed exceptional diagnostic performance: ROC analysis showed 0.998 AUC (cutoff=0.125), 94.8% concordance with IDEXX ELISA, and the intra- and inter-batch coefficient of variation are both less than 5%. The experimental results indicate that the indirect ELISA detection method based on BVDV rE2 exhibits good sensitivity, specificity, and stability. And a stable serological tool for BVDV surveillance and vaccine efficacy evaluation in cattle populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.